title: Lymphohematopoietic stem cell engraftment.
abstract: Traditional dogma has stated that space needs to be opened by cytoxic myeloablative therapy in order for marrow stem cells to engraft. Recent work in murine transplant models, however, indicates that engraftment is determined by the ratio of donor to host stem cells, i.e., stem cell competition. One hundred centigray whole body irradiation is stem cell toxic and nonmyelotoxic, thus allowing for higher donor chimerism in a murine syngeneic transplant setting. This nontoxic stem cell transplantation can be applied to allogeneic transplant with the addition of a tolerizing step; in this case presensitization with donor spleen cells and administration of CD40 ligand antibody to block costimulation. The stem cells that engraft in the nonmyeloablated are in G0, but are rapidly induced (by 12 hours) to enter the S phase after in vivo engraftment. Exposure of murine marrow to cytokines (IL-3, IL-6, IL-11 and steel factor) expands progenitor clones, induces stem cells into cell cycle, and causes a fluctuating engraftment phenotype tied to phase of cell cycle. These data indicate that the concepts of stem cell competition and fluctuation of stem cell phenotype with cell cycle transit should underlie any new stem cell engraftment strategy.
authors.affiliation: University of Massachusetts Medical Center, Worcester 01605, USA. Peter.Quesenberry@banyan.ummed.edu
authors.forename: P J
authors.initials: PJ
authors.lastname: Quesenberry
authors.forename: F M
authors.initials: FM
authors.lastname: Stewart
authors.forename: S
authors.initials: S
authors.lastname: Zhong
authors.forename: H
authors.initials: H
authors.lastname: Habibian
authors.forename: C
authors.initials: C
authors.lastname: McAuliffe
authors.forename: J
authors.initials: J
authors.lastname: Reilly
authors.forename: J
authors.initials: J
authors.lastname: Carlson
authors.forename: M
authors.initials: M
authors.lastname: Dooner
authors.forename: S
authors.initials: S
authors.lastname: Nilsson
authors.forename: S
authors.initials: S
authors.lastname: Peters
authors.forename: G
authors.initials: G
authors.lastname: Stein
authors.forename: J
authors.initials: J
authors.lastname: Stein
authors.forename: R
authors.initials: R
authors.lastname: Emmons
authors.forename: B
authors.initials: B
authors.lastname: Benoit
authors.forename: I
authors.initials: I
authors.lastname: Bertoncello
authors.forename: P
authors.initials: P
authors.lastname: Becker
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D002454:Cell Differentiation; D016207:Cytokines / Q000494:pharmacology; D006084:Graft Rejection / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D008214:Lymphocytes / Q000166:cytology* / Q000276:immunology; D051379:Mice; D018183:Transplantation Chimera; D014184:Transplantation, Homologous / Q000276:immunology*
chemical_list: D016207:Cytokines